Author/Authors :
Islam، نويسنده , , M.Ashequl and Blankenship، نويسنده , , James C and Balog، نويسنده , , Craig and Iliadis، نويسنده , , Elias A and Lincoff، نويسنده , , A.Michael and Tcheng، نويسنده , , James E and Califf، نويسنده , , Robert M and Topol، نويسنده , , Eric J، نويسنده ,
Abstract :
In the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT), abciximab reduced ischemic complications of stent implantation at 30 days and 6 months. The responsible mechanisms remain unclear. We sought to determine if abciximab decrease
